Literature DB >> 12683654

Umbilical arterial Doppler sonography for fetal surveillance in pregnancies complicated by pregestational diabetes mellitus.

D Maulik1, A Lysikiewicz, G Sicuranza.   

Abstract

Antepartum fetal surveillance constitutes an essential component of the standards of care in managing pregnancies complicated by pregestational diabetes mellitus. Fetal hyperglycemia is associated with increased oxidative metabolism, hypoxemia and increased brain and renal perfusion without any significant changes in fetoplacental perfusion. Human cordocentesis data show that fetal hypoxemia and acidemia are associated with changes in the umbilical arterial Doppler indices in maternal diabetes mellitus complicated by fetal growth restriction or pre-eclampsia. Consistent with this, observational studies suggest significant diagnostic efficacy of the Doppler method in diabetic pregnancies complicated by vasculopathy, and in the presence of fetal growth restriction or hypertension. However, the relationship between abnormal umbilical arterial Doppler indices and the quality of glycemic control remains unproved. Although there are no randomized trials specifically addressing this issue, existing evidence suggests that Doppler velocimetry of the umbilical artery may be beneficial for antepartum fetal surveillance in diabetic pregnancies complicated by vasculopathy, fetal growth restriction or hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12683654     DOI: 10.1080/jmf.12.6.417.422

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  2 in total

Review 1.  Diversity of potassium channels in human umbilical artery smooth muscle cells: a review of their roles in human umbilical artery contraction.

Authors:  Pedro Martín; Alejandro Rebolledo; Ana Rocio Roldán Palomo; Melisa Moncada; Luciano Piccinini; Verónica Milesi
Journal:  Reprod Sci       Date:  2013-09-30       Impact factor: 3.060

2.  Maternal diabetes and the fetal heart.

Authors:  L K Hornberger
Journal:  Heart       Date:  2006-05-12       Impact factor: 5.994

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.